Additional Study Information: Subjects who undergo a kidney transplant require long term use of anti-rejection (immunosuppressive)drugs to prevent their body's immune system from attacking and damaging the newly transplanted kidney (rejection).The purpose of this study is to evaluate benefits and risks of two combinations(regimens) of immunosuppressive therapies: Thymoglobulin followed by Belatacept + Everolimus (EVL) as compared to thyroglobulin followed by Tacrolimus (TAC) + Mycophenolate Mofetil (MMF), which is an accepted standard of care. In addition to one of the above regimens, patients will receive a brief (10 days or less) course of treatment with a steroid medication.This is normal standard care at Columbia University Medical Center/New York Presbyterian Hospital (CUMC/NYPH).